The final countdown for the Anlon Healthcare IPO has begun, with just a few hours left before the subscription window closes. Investor participation has been strong since day one, and all eyes are now on the grey market premium (GMP), which has sparked hopes of a positive listing rally.
Also Read : Divi’s Labs Stock Set for 15% Upside: Nuvama Reveals 3 Growth Drivers
The IPO, which opened for subscription on August 26, 2025, is generating interest not only because of its sectoral strength but also due to its steady grey market activity. Let’s dive into the latest updates on subscription numbers, GMP trends, key dates, and what analysts are saying about the company’s prospects.
Strong Investor Demand from Day One
Anlon Healthcare’s IPO has witnessed robust demand across investor categories. According to the latest data as of the morning of August 29, the issue has been subscribed more than 4 times overall.
- Retail Investors: The highlight of this IPO has been the overwhelming response from retail investors. Their quota was oversubscribed 28 times, reflecting strong confidence in the company’s growth story.
- Non-Institutional Investors (NIIs): This category recorded more than 3 times subscription, showcasing healthy interest from high-net-worth individuals.
- Qualified Institutional Buyers (QIBs): The QIB segment showed more cautious participation, getting subscribed 1.01 times so far.
The subscription numbers clearly indicate that retail enthusiasm has been the driving force behind the success of this IPO.
Grey Market Premium (GMP) Holds Firm
One of the most closely tracked indicators during an IPO is the Grey Market Premium (GMP). For Anlon Healthcare, the GMP has been steady at ₹5 per share on the last day of bidding.
At the upper price band of ₹91, this suggests a potential listing price of around ₹96, translating into a 5–6% premium over the issue price if current sentiment continues.
While GMP often serves as an early signal of market expectations, it is important to remember that it is an unofficial metric. Market mood, global cues, and sectoral news can easily influence the final listing price.
Key IPO Dates to Remember
- Issue Close Date: August 29, 2025
- Basis of Allotment: September 1, 2025
- Refunds Initiation: September 2, 2025
- Credit of Shares to Demat Accounts: September 2, 2025
- Listing Date (Tentative): September 3, 2025
These timelines mean investors won’t have to wait too long to know whether they’ve secured allotment and how the stock performs on its debut.
Brokerage Views on Anlon Healthcare IPO
Brokerage houses have largely taken a cautiously optimistic view of the IPO.
Leading domestic brokerage Anand Rathi has issued a “Subscribe Long Term” rating, citing the company’s attractive valuations and strong market potential.
The report highlighted that:
- At the upper price band, Anlon Healthcare is valued at a P/E ratio of 19.0x based on FY25 projected earnings.
- Its EV/EBITDA stands at 16.7x, which is considered reasonable given the industry benchmarks.
- The company’s post-issue market capitalization is estimated at ₹4,836 million, reflecting growth potential.
This suggests that while short-term listing gains may be moderate, the long-term prospects look promising for investors with patience.
What Does Anlon Healthcare Do?
Founded in 2013, Anlon Healthcare is a pharmaceutical company engaged in the production of:
- High-purity pharmaceutical intermediates
- Active Pharmaceutical Ingredients (APIs)
These components are critical building blocks in the formulation of:
- Prescription medicines
- Nutraceuticals
- Personal care products
- Veterinary and animal healthcare products
The company has built a reputation for consistent quality and compliance, which has helped it gain recognition among global pharmaceutical clients. With the API market projected to grow rapidly due to increasing healthcare demand, Anlon Healthcare is well-placed to tap into this momentum.
Stock Market Buzz and Investor Sentiment
The IPO has not only attracted retail investors but has also sparked discussions among market watchers. The fact that the issue was fully subscribed on the first day reflects the positive sentiment.
Market experts believe that the steady GMP indicates that while the stock may not deliver blockbuster listing gains, it is expected to provide stability and gradual growth. The pharma sector’s defensive nature also makes it appealing amid market volatility.
Final Thoughts
With subscription crossing 4 times overall, retail bids flooding the market, and GMP holding steady, the Anlon Healthcare IPO has emerged as one of the most closely tracked issues this month.
The company’s strong fundamentals, coupled with a stable valuation and long-term industry growth prospects, make it an interesting pick for investors. While immediate listing gains may remain in the 5–6% range, the real story lies in long-term value creation.
For investors eyeing both defensive stocks and pharmaceutical growth, Anlon Healthcare could be a valuable addition to their portfolios.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investors are advised to consult their financial advisor before making any investment decisions.
